|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:cobicistat
gptkb:darunavir
gptkb:tenofovir_alafenamide
emtricitabine
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AR21
|
|
gptkbp:combinationTherapy
|
yes
|
|
gptkbp:contraindication
|
severe liver impairment
concomitant use with certain drugs
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
gptkb:tablet
fixed-dose combination tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Symtuza
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
HIV-1 protease inhibitor (darunavir), pharmacokinetic enhancer (cobicistat), nucleoside reverse transcriptase inhibitor (emtricitabine), nucleotide reverse transcriptase inhibitor (tenofovir alafenamide)
|
|
gptkbp:onceDaily
|
yes
|
|
gptkbp:pregnancyCategory
|
N
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
rash
|
|
gptkbp:website
|
https://www.symtuza.com/
|
|
gptkbp:bfsParent
|
gptkb:DB06151
gptkb:Janssen_Sciences
gptkb:DB04876
|
|
gptkbp:bfsLayer
|
7
|